Treatment of clomiphene citrate‐resistant polycystic ovarian syndrome with pure follicle‐stimulating hormone or human menopausal gonadotropin

McFaul, PB; Ai, Traub; Thompson, Willard O.

doi:10.1016/0020-7292(91)90372-c

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A pregnancy rate of about 80% is achieved with conventional regimens [1], with a high frequency (about 30%) of multiple births [2] due to multiple follicular development. Similar results have been reported with human menopausal gonadotrophins and urinary pure follicle-stimulating hormone (pFSH) [3]. Low-dose regimens [4] reduce these risks.…”

Section: Introductionsupporting

confidence: 71%

Ovarian Stimulation with Low-Dose Pure Follicle-Stimulating Hormone in Polycystic Ovarian Syndrome Anovulatory Patients:Effect of Long-Term Pretreatment with Gonadotrophin-Releasing Hormone Analogue

Vegetti

Testa

Ragni

et al. 1998

Gynecol Obstet Invest

View full text Add to dashboard Cite

A randomised clinical trial was performed to evaluate the effect of a 3-month gonadotrophin-releasing-hormone analogue (GnRH-a) in one cycle of ovulation induction with low-dose pure follicle-stimulating hormone (pFSH) in patients with polycystic ovarian syndrome (PCOS) anovulation. Twenty patients with chronic anovulation due to PCOS were randomised to ovulation induction with pFSH administered in a low-dose schedule with (10 patients) and without (10 patients) a 3-month pretreatment with GnRH-a. Ultrasound scan only monitoring of follicular growth, evaluation of plasmatic oestradiol at the day of triggering of ovulation with human chorionic gonadotrophin 5,000 IU and evaluation of plasmatic progesterone 8 days after were the main outcome measures. Ovulation occurred in 9 patients treated with pFSH and in 2 patients treated with GnRH-a plus pFSH. Five pregnancies in the pFSH group and no pregnancy in the GnRH-a group were obtained. Five cycles were stopped due to multifollicular growth in the GnRH-a group and 1 in the pFSH group. Pretreatment with a 3-month administration of a GnRH-a did not improve the ovulation rate and pregnancy rate in PCOS patient ovulation induction with low-dose pFSH.

show abstract

Section: Introductionsupporting

confidence: 71%

Ovarian Stimulation with Low-Dose Pure Follicle-Stimulating Hormone in Polycystic Ovarian Syndrome Anovulatory Patients:Effect of Long-Term Pretreatment with Gonadotrophin-Releasing Hormone Analogue

Vegetti

Testa

Ragni

et al. 1998

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…However, due to the high sensitivity of the PCO to gonadotrophin stimulation and its propensity to multiple follicular development, this treatment regimen is plagued by a high frequency of multiple pregnancies and OHSS (Wang and Gemzell, 1980). The use of urinary human FSH has done little to remedy this situation (Garcea et al, 1985;McFaul et al, 1990). Following the initial publication of Seibel et aL (1984), several investigators have examined the utility of a chronic low dose regimen of FSH in an attempt to reduce the complication rate (Poison et al, 1987;Hamilton-Fairley et al, 1991;Shoham et al, 1991;Dale et al, 1993;Scheele et al, 1993a;Homburg et al, 1995a).…”

Section: Treatmentmentioning

confidence: 99%

Polycystic ovary syndrome--from gynaecological curiosity to multisystem endocrinopathy

Homburg

1996

Human Reproduction

191

View full text Add to dashboard Cite

Recent progress in the diagnosis, pathophysiology, long-term ramifications and treatment of polycystic ovary syndrome has been rapid but the pathogenesis remains a challenging enigma and the treatment symptomatic. Objective ultrasound criteria for diagnosis are being formulated and have enabled an appreciation of the true prevalence and the associated clinical and biochemical manifestations. Although a heterogeneous syndrome, the final common pathway seems to involve a dysregulation of enzymes responsible for ovarian androgen biosynthesis, possibly influenced by insulin, growth factors and luteinizing hormone. A single gene defect, inherited in an autosomal dominant pattern, has been proposed. The treatment is necessarily symptomatic, depending on the needs of the patient. Long-term deleterious sequelae now emerging may demand suppression of the syndrome earlier in life. As the most prevalent cause of anovulatory infertility, a further elucidation of the basic pathogenesis is needed to allow the application of more specific and successful modalities of treatment.

show abstract

Treatment of clomiphene citrate‐resistant polycystic ovarian syndrome with pure follicle‐stimulating hormone or human menopausal gonadotropin

Cited by 2 publications

References 0 publications

Ovarian Stimulation with Low-Dose Pure Follicle-Stimulating Hormone in Polycystic Ovarian Syndrome Anovulatory Patients:Effect of Long-Term Pretreatment with Gonadotrophin-Releasing Hormone Analogue

Ovarian Stimulation with Low-Dose Pure Follicle-Stimulating Hormone in Polycystic Ovarian Syndrome Anovulatory Patients:Effect of Long-Term Pretreatment with Gonadotrophin-Releasing Hormone Analogue

Polycystic ovary syndrome--from gynaecological curiosity to multisystem endocrinopathy

Contact Info

Product

Resources

About